Podcast: Building And Scaling Your Workforce: The Importance Of A Flexible Delivery Model In 2024 & Beyond

Creative Science
• Source: Shutterstock

Talent acquisition plays a central role in fostering creativity and innovation within any organization. In today’s highly competitive and fast-moving life sciences sector, it’s more important than ever. Tune into this free podcast to gain valuable insights on maintaining a competitive edge through innovative recruitment and retention strategies.

Listen now, and explore topics including:

  • The importance of organizational culture, flexible working, a diverse leadership and meaningful work when identifying and retaining talent
  • The current skills gaps in the sector
  • Operational challenges facing life sciences looking to scale on a global level, and the critical role of a flexible staffing model
  • Key considerations when scaling your workforce
  • Balancing scientific and technological expertise in recruitment
  • The impact of emerging technologies, such as gene editing, personalized medicines and AI on talent acquisition
  • Reflections on 2023, and tips for revolutionizing the talent ecosystem in 2025

Citeline · Building And Scaling Your Workforce: The Importance Of A Flexible Delivery Model In 2024 & Beyond

Open Media

More from Leadership

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By 

Series B cash will be used to advance its Stargardt disease gene therapy.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

More from Scrip

In partnership with

Podcast Series: Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development

Sponsored by:

Making medicines more affordable to the NHS

Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system

Sponsored by:

Oncology R&D trends at a glance

Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.